» Articles » PMID: 26467275

Haploidentical Bone Marrow Transplantation in 2015 and Beyond

Overview
Journal Curr Oncol Rep
Publisher Current Science
Specialty Oncology
Date 2015 Oct 16
PMID 26467275
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

On the face of the lack of HLA-identical sibling stem cell donors for all individuals needing an allograft, the use of alternative donors is gaining popularity. Matched unrelated donors and cord bloods have become very expensive and unaffordable for most people living in developing countries. Grafting allogeneic haploidentical stem cells has become an option with a great future, mainly if the procedure is conducted in a way to cut down expenses, such as the use of reduced-intensity conditioning regimens, outpatient conduction of the procedures, and use of post-transplant cyclophosphamide. The long-term results of allografting haploidentical stem cells seem to be similar to those of grafting cord blood stem cells. The improvement of the procedures to conduct haploidentical stem cell transplantation will most likely result in more individuals gaining access to this type of treatments, critical in the current practice of hematology.

Citing Articles

Bone Marrow Transplantation in Patients With Acute Leukemia In Cuba: Results From the Last 30 Years and New Opportunities Through International Collaboration.

Carnot Uria J, Cruz C, Munio Perurena J, Torres Yribar W, Diego de la Campa J, Del Castillo Carrillo C J Glob Oncol. 2018; 4:1-7.

PMID: 30582434 PMC: 7010424. DOI: 10.1200/JGO.18.00109.


Review of Haploidentical Hematopoietic Cell Transplantation.

Khan M, Bashir Q, Chaudhry Q, Ahmed P, Satti T, Mahmood S J Glob Oncol. 2018; 4:1-13.

PMID: 30521413 PMC: 7010419. DOI: 10.1200/JGO.18.00130.


Choice of Unmanipulated T Cell Replete Graft for Haploidentical Stem Cell Transplant and Posttransplant Cyclophosphamide in Hematologic Malignancies in Adults: Peripheral Blood or Bone Marrow-Review of Published Literature.

Farhan S, Peres E, Janakiraman N Adv Hematol. 2016; 2016:6950346.

PMID: 27118973 PMC: 4826912. DOI: 10.1155/2016/6950346.

References
1.
Guinan E, Boussiotis V, Neuberg D, Brennan L, Hirano N, Nadler L . Transplantation of anergic histoincompatible bone marrow allografts. N Engl J Med. 1999; 340(22):1704-14. DOI: 10.1056/NEJM199906033402202. View

2.
Kanda J, Lopez R, Rizzieri D . Alemtuzumab for the prevention and treatment of graft-versus-host disease. Int J Hematol. 2011; 93(5):586-593. DOI: 10.1007/s12185-011-0802-2. View

3.
Jaime-Perez J, Heredia-Salazar A, Cantu-Rodriguez O, Gutierrez-Aguirre H, Villarreal-Villarreal C, Mancias-Guerra C . Cost structure and clinical outcome of a stem cell transplantation program in a developing country: the experience in northeast Mexico. Oncologist. 2015; 20(4):386-92. PMC: 4391759. DOI: 10.1634/theoncologist.2014-0218. View

4.
Fuchs E . Haploidentical transplantation for hematologic malignancies: where do we stand?. Hematology Am Soc Hematol Educ Program. 2012; 2012:230-6. PMC: 3657706. DOI: 10.1182/asheducation-2012.1.230. View

5.
Svahn B, Ringden O, Remberger M . Long-term follow-up of patients treated at home during the pancytopenic phase after allogeneic haematopoietic stem cell transplantation. Bone Marrow Transplant. 2005; 36(6):511-6. DOI: 10.1038/sj.bmt.1705096. View